Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2005

View Archived Issues

SU-11248 effective in malignant pleural effusion model

Mechanisms underlying CAT-354's efficacy in asthma

U-74500A helps protect against antipsychotic-induced tardive dyskinesia

In vivo evidence for BN-82451 efficacy in Parkinson's disease

Further data on the antiarthritic effects of abatacept

Dimethylfumarate as a therapy for MS

Shire: Q1 developments

Depomed and New River sign development and license agreement

Kosan studies KOS-1022 in advanced hematologic malignancies

Portola and Astellas collaborate in thrombosis and atherosclerosis

Phase II trial for FavId in Europe

OncoVEX(GM-CSF) cleared for phase II study in malignant melanoma

Aloxi gets first European launch in Ireland

AS-1404 studied for ovarian cancer in new phase II trial

European orphan drug designation for Oncophage in renal cell carcinoma

Virulizin granted orphan drug status in Europe

Phase IIb study of NP-50301 for dry eye syndrome completes enrollment

TorreyPines Therapeutics files IND for Alzheimer's drug NGX-267

FASgen secures funding for FAS-20013 in MDR-TB

PediaMed studies GI dysfunction in children with autism

"Rotaviruses", the latest addition to the Drug R&D Backgrounders series, now available

LBH-589 increases immunosuppression induced by FK-778 and everolimus

New data on the therapeutic benefits of belatacept in renal transplantation

Update on the efficacy of repinotan in acute stroke

Recent patents describe new antiinfective agents

New agents for asthma and other respiratory diseases reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.